BMS caffeine study
This article was originally published in The Tan Sheet
Executive Summary
Bristol Myers-Squibb requests teleconference with FDA in "near future" to discuss several questions generated by agency comments on firm's clinical study proposal for trial comparing effects of aspirin/acetaminophen/ caffeine in varying doses with acetaminophen 1,000 mg alone. Excedrin marketer submitted study protocol in July 2001; FDA responded in February that acetaminophen-only arm is unnecessary, trial should include second pain model other than headache (1"The Tan Sheet" Feb. 25, 2002, p. 9). In May 31 submission, BMS maintains "we believe that many of the issues raised [by FDA] will be answered by providing the agency with a full protocol, rather than the protocol outline we submitted" in July. Complete protocol will be submitted after the teleconference, firm says...
You may also be interested in...
BMS Caffeine Adjuvancy Study Acetaminophen-Only Arm Unnecessary – FDA
An acetaminophen-only treatment arm in Bristol-Myers Squibb's planned clinical study on the efficacy of different caffeine doses in analgesic adjuvancy is unnecessary, FDA says in a recent letter
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.